MCL unlocked: Mastering Mantle Cell Lymphoma
Series of Webinars on Mantle Cell Lymphoma
Learning objectives:
2. Apply Personalized Treatment Approaches: Tailor treatment strategies (chemotherapy, targeted therapies, stem cell transplantation) based on risk profiles to improve patient outcomes.
3. Manage Relapse effectively: Equipping HCPs with the knowledge and skills of assessing and treating re lapses effectively through understanding the pathophysiology, identifying the clinical and molecular markers, and evaluating available therapeutic options, such as targeted therapies, chemotherapy, and stem cell transplantation.
4. Manage Toxicities Effectively: Recognize and proactively manage toxicities associated with current and emerging MCL therapies, optimizing patient safety and quality of life.
5. Implement Maintenance and Long-Term Care: Integrate maintenance therapies to prolong remission and develop strategies for managing relapsed/refractory MCL and preventing secondary malignancies.
6. Utilize Biomarkers for Prediction and Monitoring: Apply genomic profiling and liquid biopsy to predict resistance, monitor disease progression, and guide treatment decisions.
7. Enhance Patient Outcomes and Quality of Life: Improve management of MCL by tailoring therapies and providing supportive care to maintain or improve patient quality of life.
July 2025
1 CE credit
Webinar 1: Advancing Risk Stratification in Mantle Cell Lymphoma: From Prognostic Markers to Personalized Care
Join the discussion of current risk stratification models and review of existing tools like Ki-67, cyclin D1 expression, and TP53 mutations; the role of gene expression profiling, next-generation sequencing (NGS), and liquid biopsies in MCL; how to use risk profiles to guide treatment decisions, including chemotherapy, targeted therapies, and stem cell transplantation; and real-world examples of how to integrate risk stratification into clinical practice.
August 2025
1 CE credit
Webinar 2: Overcoming Resistance to Targeted Therapies in Mantle Cell Lymphoma
Join the discussion of the mechanism of action of BTK inhibitors, blocking BTK signaling and leading to apoptosis of malignant B-cells; downstream signaling pathways, including NF-kB, PLCγ2, and PI3K AKT; clinical efficacy of BTK Inhibitors; mechanisms of resistance to BTK inhibitors; and next-generation BTK inhibitors.
September 2025
1 CE credit
Webinar 3: Managing Toxicity and Improving Quality of Life in MCL Treatment
Join the discussion of toxicities of current and emerging therapies, common side effects and how to manage them; best practices for early identification, prevention, and management of side effects such as cytopenias, infections, and cardiac toxicity; patients who are at high risk for severe side effects based on comorbidities, age, and therapy; how to integrate supportive care strategies (e.g., growth factors, prophylactic antibiotics) into treatment regimens to improve outcomes and quality of life.
October 2025
1 CE credit
Webinar 4: Relapse, Secondary Malignancies, and Improving Long-Term Survival in Mantle Cell Lymphoma
Join the discussion of current and emerging treatments for relapsed mcl, including CAR T-cell therapy, bispecific antibodies, and immunomodulatory agents; the role of maintenance therapies like rituximab or lenalidomide in prolonging remission and reducing relapse rates; strategies for monitoring and preventing secondary cancers in mcl patients, especially in those who have undergone intensive treatments like stem cell transplants; how to balance the aggressive treatment of MCL with the long term health and well-being of patients, focusing on survivorship care plans.
November 2025
1 CE credit
Webinar 5: Innovative Treatment Approaches, Clinical Trials, and Long-Term Care for Mantle Cell Lymphoma (MCL)
Join the discussion of BTKi preference; PI3K inhibitors and other targeted therapies in cases of BTK resistance or intolerance, PI3K inhibitors or BCL-2 inhibitors are alternative options; allogeneic stem cell transplantation; genetic and molecular profiling of the tumor (e.g., mutations in BTK, TP53, MYD88, etc.); novel agents: next-generation BTK inhibitors, bispecific antibodies, CAR T-cell therapy, and combination therapies to overcome resistance and improve long-term remission.
